Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.

Tapaninen T, Olkkola AM, Tornio A, Neuvonen M, Elonen E, Neuvonen PJ, Niemi M, Backman JT.

Clin Transl Sci. 2019 Oct 30. doi: 10.1111/cts.12716. [Epub ahead of print]

PMID:
31664782
2.

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts.

Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS.

Cancers (Basel). 2019 Apr 24;11(4). pii: E577. doi: 10.3390/cancers11040577.

3.

Enantiospecific Pharmacogenomics of Fluvastatin.

Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvärinen M, Tapaninen T, Backman JT, Niemi M.

Clin Pharmacol Ther. 2019 Sep;106(3):668-680. doi: 10.1002/cpt.1463. Epub 2019 May 14.

4.

Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation.

Tornio A, Filppula AM, Niemi M, Backman JT.

Clin Pharmacol Ther. 2019 Jun;105(6):1345-1361. doi: 10.1002/cpt.1435. Epub 2019 Apr 20.

5.

Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Drug Metab Dispos. 2019 Apr;47(4):377-385. doi: 10.1124/dmd.118.084665. Epub 2019 Jan 10.

PMID:
30630815
6.

Response to "Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?"

Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2019 Feb;105(2):322. doi: 10.1002/cpt.1195. Epub 2018 Sep 17. No abstract available.

PMID:
30226021
7.

CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.

Holmberg MT, Tornio A, Paile-Hyvärinen M, Tarkiainen EK, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacol Ther. 2019 Feb;105(2):448-457. doi: 10.1002/cpt.1177. Epub 2018 Aug 20.

PMID:
29998574
8.

Cytochrome P450 in Pharmacogenetics: An Update.

Tornio A, Backman JT.

Adv Pharmacol. 2018;83:3-32. doi: 10.1016/bs.apha.2018.04.007. Review.

PMID:
29801580
9.

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel.

Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2019 Jan;105(1):219-228. doi: 10.1002/cpt.1099. Epub 2018 Aug 9.

10.

Response to "Influence of Diabetes on Antiplatelet Drug Efficacy".

Tornio A, Palmer CNA, Doney ASF.

Clin Pharmacol Ther. 2018 Apr;103(4):573. doi: 10.1002/cpt.1002. Epub 2018 Feb 22. No abstract available.

PMID:
29468659
11.

Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.

Doki K, Darwich AS, Achour B, Tornio A, Backman JT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2018 May;84(5):972-986. doi: 10.1111/bcp.13533. Epub 2018 Mar 6.

12.

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.

Itkonen MK, Tornio A, Filppula AM, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2018 Sep;104(3):495-504. doi: 10.1002/cpt.947. Epub 2017 Dec 23.

13.

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions.

Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT.

Drug Metab Dispos. 2018 Feb;46(2):141-150. doi: 10.1124/dmd.117.078162. Epub 2017 Nov 14.

PMID:
29138287
14.

A common missense variant of LILRB5 is associated with statin intolerance and myalgia.

K Siddiqui M, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, Abelega NU, Carr D, Bloch K, Hallberg P, Yue QY, Pearson ER, Colhoun HM, Morris AD, Dow E, George J, Pirmohamed M, Ridker PM, Doney ASF, Alfirevic A, Wadelius M, Maitland-van der Zee AH, Chasman DI, Palmer CNA; PREDICTION-ADR Consortium.

Eur Heart J. 2017 Dec 21;38(48):3569-3575. doi: 10.1093/eurheartj/ehx467.

15.

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects.

Neuvonen M, Tarkiainen EK, Tornio A, Hirvensalo P, Tapaninen T, Paile-Hyvärinen M, Itkonen MK, Holmberg MT, Kärjä V, Männistö VT, Neuvonen PJ, Pihlajamäki J, Backman JT, Niemi M.

Basic Clin Pharmacol Toxicol. 2018 Mar;122(3):341-345. doi: 10.1111/bcpt.12916. Epub 2017 Nov 17.

16.

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.

Hirvensalo P, Tornio A, Neuvonen M, Tapaninen T, Paile-Hyvärinen M, Kärjä V, Männistö VT, Pihlajamäki J, Backman JT, Niemi M.

Clin Pharmacol Ther. 2018 Jul;104(1):158-168. doi: 10.1002/cpt.891. Epub 2017 Nov 6.

17.

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.

Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF.

Clin Pharmacol Ther. 2018 Feb;103(2):281-286. doi: 10.1002/cpt.780. Epub 2017 Sep 19.

18.

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.

Tornio A, Neuvonen PJ, Niemi M, Backman JT.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):83-95. Epub 2016 Aug 31. Review.

PMID:
27548563
19.

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Drug Metab Dispos. 2016 Aug;44(8):1364-71. doi: 10.1124/dmd.116.070375. Epub 2016 Jun 3.

PMID:
27260150
20.

High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population.

Pietarinen P, Tornio A, Niemi M.

Basic Clin Pharmacol Toxicol. 2016 Sep;119(3):291-6. doi: 10.1111/bcpt.12590. Epub 2016 May 14.

21.

Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.

Drug Metab Dispos. 2015 Nov;43(11):1655-60. doi: 10.1124/dmd.115.065938. Epub 2015 Sep 1.

PMID:
26329790
22.

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.

Tornio A, Vakkilainen J, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M.

Pharmacogenet Genomics. 2015 Aug;25(8):382-7. doi: 10.1097/FPC.0000000000000148.

PMID:
26020121
23.

Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.

Tarkiainen EK, Tornio A, Holmberg MT, Launiainen T, Neuvonen PJ, Backman JT, Niemi M.

Br J Clin Pharmacol. 2015 Nov;80(5):1131-8. doi: 10.1111/bcp.12667. Epub 2015 Jun 11.

24.

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.

Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacol Ther. 2015 Jun;97(6):650-8. doi: 10.1002/cpt.101. Epub 2015 May 9.

PMID:
25704243
25.

Effect of grapefruit juice on the bioactivation of prasugrel.

Holmberg MT, Tornio A, Hyvärinen H, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M.

Br J Clin Pharmacol. 2015 Jul;80(1):139-45. doi: 10.1111/bcp.12581. Epub 2015 Jun 1.

26.

Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.

Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2014 Oct;96(4):498-507. doi: 10.1038/clpt.2014.141. Epub 2014 Jun 27.

PMID:
24971633
27.

Grapefruit juice inhibits the metabolic activation of clopidogrel.

Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacol Ther. 2014 Mar;95(3):307-13. doi: 10.1038/clpt.2013.192. Epub 2013 Sep 25.

PMID:
24067745
28.

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.

Filppula AM, Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2013 Sep;94(3):383-93. doi: 10.1038/clpt.2013.92. Epub 2013 May 8.

PMID:
23657159
29.

Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects.

Holmberg MT, Tornio A, Joutsi-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, Niemi M, Backman JT.

Br J Clin Pharmacol. 2013 Jun;75(6):1488-96. doi: 10.1111/bcp.12026.

30.

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.

Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Trends Pharmacol Sci. 2012 Jun;33(6):312-22. doi: 10.1016/j.tips.2012.03.001. Epub 2012 Apr 2. Review.

PMID:
22475684
31.

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ.

Drug Metab Dispos. 2009 Dec;37(12):2359-66. doi: 10.1124/dmd.109.029728. Epub 2009 Sep 22.

PMID:
19773535
32.

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.

Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2008 Sep;84(3):403-11. doi: 10.1038/clpt.2008.34. Epub 2008 Mar 26.

PMID:
18388877
33.

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.

Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2008 Jan;36(1):73-80. Epub 2007 Oct 3.

PMID:
17913794
34.

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.

Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2007 May;63(5):463-9. Epub 2007 Feb 27.

PMID:
17333159
35.

The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.

Tornio A, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2006 Aug;62(8):645-51. Epub 2006 Jul 11.

PMID:
16832679
36.

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.

Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2006 Jun;62(6):463-72. Epub 2006 Apr 27.

PMID:
16758263
37.

Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.

Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT.

Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8.

Supplemental Content

Loading ...
Support Center